113 results about "Sacroiliitis" patented technology

The invention discloses a deep learning algorithm-based spinal MRI precise synthesis CT image processing system and method for central axis type spinal arthritis, and the system comprises a data obtaining unit which is used for obtaining a three-dimensional T1 weighted multi-gradient echo sequence, a T2 weighted sequence and a water-fat separation sequence which are obtained through the magnetic resonance imaging of the spinal column of a target user; the spatial registration unit is used for inputting the multi-sequence data into a deformable registration network so as to carry out spatial registration on the multi-modal features; the feature processing unit is used for carrying out feature fusion on the registered multi-modal features and carrying out double-domain splitting based on an anatomical attention gating mechanism to obtain skeleton features and soft tissue features; and the image fusion unit is used for synthesizing a synthesized CT image with an HU value corresponding to the spine of the target user based on the skeleton features and the soft tissue features, so that radiation-free high-precision CT image acquisition is realized, the diagnosis grading requirement on the axis type spine joint in the spine can be met, and the influence of radiation on the target user can be reduced.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

A sacroiliac (SI) joint implant assembly addresses SI joint dysfunction and degenerative sacroiliitis. The assembly includes a first implant body, a second implant body, and a piezoelectric layer positioned between them. The piezoelectric layer generates electrical charges when subjected to mechanical stress, stimulating bone growth and enhancing stability of the SI joint after surgery. The implant bodies may feature non-planar surfaces to distribute compressive and shear forces unevenly across the piezoelectric layer. The assembly can be secured using fasteners such as screws, pins, or brackets, and may include porous or fenestrated bodies made from materials like titanium or polymers. Some implant assemblies are designed for minimally invasive surgical procedures, with configurations that allow for precise placement using guide wires and imaging techniques. The assembly aims to stabilize the SI joint and promote bone fusion, leveraging the piezoelectric effect to improve the overall efficacy of the fusion procedure.

The invention relates to the technical field of medical image auxiliary diagnosis, and provides an intervertebral joint osteoarthritis image feature evaluation method based on deep learning, which can synchronously identify five types of FJOA image features such as joint space stenosis, osteophyte, hypertrophy, subchondral bone erosion and subchondral cyst, and improves the comprehensiveness and efficiency of evaluation. The nnU-Net model is adopted to perform high-precision segmentation on an intervertebral joint region, so that the positioning precision is effectively improved; by introducing a shared feature extraction network based on ResNet-18 and five parallel classification sub-networks, joint modeling of multi-scale semantic information is realized, and the recognition accuracy and generalization ability of the model are improved; according to the method, a Grad-CAM technology is combined to generate an activation thermodynamic diagram, a model interpretation basis is superposed to an original image, visual display of an evaluation result is realized, interpretability and clinical applicability of the model are enhanced, and FJOA image features in axial lumbar vertebra CT images from two central data sets can be quantitatively evaluated so as to comprehensively quantify individual FJOA image features.

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

The invention provides application of apoptotic cell pretreated macrophages in preparation of an osteoarthritis treatment preparation, a cell preparation and a preparation method, and relates to the technical field of biomedicine.In the embodiment of the invention, based on a mouse development model and an osteoarthritis (OA) model, it is found that in the area away from the cartilage surface, the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment, and the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment in the area away from the cartilage surface; in the macrophages, the content of the interment-related LAMP1 protein is obviously higher than that of the macrophages close to the cartilage surface area, and the expression results of TGF-beta 1 and LRG1 are respectively opposite and consistent with those of the LAMP1. The invention also finds that after the chemotactic effect of apoptotic cells on macrophages is weakened, the cellular burial effect is limited, and the cartilage matrix development disorder is caused. Based on development process inspiration, the invention provides a treatment strategy: bone marrow-derived macrophages pretreated by apoptotic cells are injected into articular cavities, and a good cartilage regeneration treatment effect can be achieved in a mouse arthritis model. In addition, the bone marrow-derived macrophages pretreated by apoptotic cells can still express TGF-beta1 after being injected into the body for 3 days, so that the effect of continuously promoting cartilage regeneration is achieved.

The present invention provides an aqueous pharmaceutical product comprising an anti-IL-17A antibody, and a use of the aqueous pharmaceutical product in the preparation of a drug for treating axial spondyloarthritis.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention discloses an arthritis imaging scoring method, system and device and a storage medium, and the key points of the technical scheme are that periodic three-dimensional reconstruction is performed on a pre-constructed arthritis phantom to obtain a plurality of periodic three-dimensional images; determining an articular surface region in each three-dimensional image, and performing joint segmentation on each articular surface region to obtain a segmented image corresponding to each articular surface region; and performing feature extraction on each segmented image to obtain a target feature corresponding to each segmented image, and performing calculation according to each target feature and the corresponding score value to obtain an image evaluation result. Dynamic monitoring can be achieved, and the local pathological state of the joint can be comprehensively reflected.

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein (I) can inhibit TNFR1 and is expected to be useful as a therapeutic agent for treating, for example, inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.The present disclosure also provides a pharmaceutical composition comprising the compound disclosed herein or a pharmaceutically acceptable salt thereof.The present disclosure also relates to a method of using the compound or a pharmaceutically acceptable salt thereof in the treatment and prevention of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa, as well as a method of preparing a medicament for this purpose. [Formula 1] TIFF0007746628000195.tif82167

The invention belongs to the field of bone nutrition powder, and particularly relates to bone nutrition powder for assisting in relieving arthritis pain and a preparation process. In the preparation, the herba eupatorii extract and the kelp extract are matched to effectively improve the arthritis pain relieving effect of the preparation, and the lophatherum gracile, the raspberry, the motherwort and the purslane are adopted to further improve the arthritis pain relieving effect of the fermented product through the processes of fermentation and the like; the preparation is applied to preparation of the bone nutrition powder, and the bone nutrition powder for assisting in relieving arthritis pain is prepared from the bone nutrition powder, protein, fat, water-soluble dietary fibers, vitamins, mineral elements and chondroitin sulfate. The obtained bone nutrition powder can effectively provide nutrition, also has an excellent health care effect, assists in relieving arthritis pain, and is excellent in performance and relatively good in application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to a new Spp1 + Carmil1 + and Spp1 + Cav1 + macrophage subgroup, a screening method and application in diagnosis and treatment of rheumatoid arthritis (RA). Aiming at the function limitation of a traditional M1 / M2 classification model, the invention proves the following new subgroup pathological interaction mechanism: osteoclast (ACP5 +) specifically releases TNFSF11 (RANKL), and is co-localized with Spp1 + Carmil1 + and Spp1 + Cav1 + subgroup space; the Spp1 + Carmil1 + subgroup secretes IL-18, and space interaction exists between the Spp1 + Carmil1 + subgroup and Treg (Foxp3 +) and Th17 (Il17a +) cells. The invention provides a novel cell marker and a targeted treatment strategy for accurate diagnosis and treatment of RA.

A preparation method of the wine comprises the following steps: 1) weighing the following raw materials in parts by weight: 18-22 parts of raw radix astragali, 13-17 parts of rhizoma drynariae, 13-17 parts of dog bone, 1-5 parts of semen strychni, 1 part of ginseng, 13-17 parts of herba epimedii, 13-17 parts of caulis spatholobi, 3-7 parts of gecko, 1 part of radix salviae miltiorrhizae, 3-7 parts of rhizoma corydalis, 1-5 parts of asarum heterotropoides, 1 part of gynostemma pentaphylla and 3-7 parts of chili; and 2) processing the raw materials into powder, placing the powder in a pottery clay jar, soaking the powder in 50-degree grain white spirit for more than half a year, performing high-temperature fermentation in summer, leaching the liquid medicine, and removing medicine residues to obtain the finished product of the fermented wine for rheumatic bone impediment. The traditional Chinese medicine has the advantages that the traditional Chinese medicine is reasonable in raw material design and convenient to prepare, has a good effect on treating various arthritis such as rheumatism, ankylosing spondylitis, rheumatic arthritis, lumbar disc herniation and hyperostosis, and has a very good popularization prospect and a very good medical economic value.

The present disclosure relates to inhibitors of miR-574-5p (SEQ ID NO: 1) for use in intra-articular treatment of a disease selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, gout, juvenile arthritis, systemic lupus erythematosus (SLE), Sjögren's syndrome and osteoporosis.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

This disclosure provides substituted 6-imidazopyridazine compounds for the modulation of IL-17A and pharmaceutical compositions thereof. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis.

The disclosure herein provides substituted 6-imidazopyridazine compounds, and pharmaceutical compositions thereof, for use in the modulation of IL-17A. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis or ankylosing spondylitis.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

Methods and kits for evaluating a clinical outcome of an autoimmune disease, specifically disease flare e.g. if the subject stops taking the biologic disease modifying anti-rheumatic drug (DMARD), by comparing biomarkers of CD45RA, TNF-alpha and / or CXCR5 from CD3+CD4+ T cell population are disclosed. In a specific embodiment, the ratio of first subset of CD3+CD4+CD45RA−TNFA+ (memory) T cells to a second subset comprising CD3+CD4+CD45RA+TNFA+ (naïve) T cell is determined, wherein an increase in the ratio indicates a disease flare state of juvenile idiopathic arthritis (JIA). In another embodiment, enrichment of CD45RA−CR5+ subset among the T cell population indicates likelihood of flare state in JIA via memory persistence enhancement through B cell interaction. In other embodiments, additional markers including IL-6, CCR6, CD152 and PD1 are also determined, and the enrichment of CD45RA-TNFA+IL-6+ subset among the T cell population indicates a likelihood of amplification of the autoimmune disease.

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, utilizing anti-IL-23A antibodies.

This application discloses a medical information data processing system and method for spondyloarthritis based on an intelligent agent learning model. The system includes: a pre-consultation intelligent agent module for generating an initial medical record in response to the patient's pre-consultation interaction data; a medical data processing intelligent agent module for acquiring the initial medical record and the patient's heterogeneous medical test data, and extracting medical entity information data related to spondyloarthritis from the initial medical record and heterogeneous medical test data using a BERT-BiLSTM-CRF hybrid model, and determining the entity information links formed by the medical entity information data using an EMR-Graph entity relationship graph model; and a medical reasoning intelligent agent module for performing reasoning analysis on the entity information links using an LSTM-TPP model to obtain the initial reasoning probability between the patient and spondyloarthritis. This module can fully consider the link relationship between medical entity information related to spondyloarthritis during the disease probability reasoning process, thereby effectively improving the accuracy of disease probability reasoning.

The invention discloses a spinal arthritis medical information data processing system and method based on an agent learning model, and the system comprises a pre-inquiry agent module which is used for responding to pre-inquiry interaction data of a patient to generate an initial medical record; the medical data processing agent module is used for acquiring the initial medical record and the heterogeneous medical detection data of the patient, and extracting medical entity information data related to the spinal arthritis from the initial medical record and the heterogeneous medical detection data by utilizing a BERT-BiLSTM-CRF hybrid model; determining an entity information link formed by the medical entity information data by using an EMR-Graph entity relation graph model; the medical reasoning agent module is used for performing reasoning analysis on an entity information link by adopting an LSTM-TPP model to obtain an initial reasoning probability between a patient and the spondyloarthritis, and can fully consider a link relationship with medical entity information related to the spondyloarthritis in a disease probabilistic reasoning process; therefore, the accuracy of disease probabilistic reasoning is effectively improved.

The invention provides a mouse-cat chimeric anti-cat CD20 antibody and an application thereof. According to the mouse-cat chimeric anti-cat CD20 antibody, variable regions of a heavy chain and a light chain of a mouse CD20 antibody and constant regions of cat IgG1 heavy chain and cat Igkappa light chain sequences are selected, and the heavy chain and the light chain of the antibody obtained after assembly respectively comprise amino acid sequences shown as SEQ ID NO.1-4. The amino acid sequence of the mouse-cat chimeric anti-cat CD20 antibody is subjected to codon optimization, expression and purification, the obtained anti-cat CD20 antibody is subjected to indirect ELISA (enzyme-linked immunosorbent assay) test, and the anti-cat CD20 antibody is proved to have antibody biological activity. After verification by a model mouse, it can be found that the mouse-cat chimeric anti-cat CD20 antibody provided by the invention can effectively relieve the swelling degree of arthritic paws, and is expected to play a role in the process of treating cat rheumatoid arthritis in the future.

To provide an etanercept pharmaceutical composition, a method for producing the same, and a method for treating a patient having rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or psoriasis.SOLUTION: A pharmaceutical composition comprising 75mM to 150mM NaCl, 5mM to 100mM arginine, 0.5% to 2% (w / v) sucrose, and 40mg to 100mg / mL etanercept, wherein the composition comprises 2. less than 0mM total additional buffer, and wherein the pH of the composition is between 6.1 and 6.5.SELECTED DRAWING: Figure 1

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded nano-micelle as well as a preparation method and application thereof. According to the invention, bromoalkanes with different chain lengths are introduced to a leonurine phenolic hydroxyl group by adopting a total synthesis method to prepare a leonurine derivative, and the drug-loaded nano-micelle is prepared by applying triptolide (TP) and the leonurine derivative. The embodiment of the invention verifies that the drug-loaded nano-micelle can reduce in-vivo and in-vitro toxicity caused by triptolide and improve the treatment effect on a mouse arthritis model induced by type II collagen. The novel triptolide compatible medicine prepared by the invention is small in toxic and side effects and has a good curative effect on rheumatoid arthritis.